Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- PALI
- Price
- 1.70
- Stock movement down
- -0.03 (-1.73%)
- Company name
- Palisade Bio Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 253.31M
- Ent value
- 251.84M
- Price/Sales
- 63326.36
- Price/Book
- 78.86
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -67.59%
- 1 year return (CAGR)
- 65.05%
- 3 year return (CAGR)
- -62.90%
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
PALI does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 63326.36 |
| Price to Book | 78.86 |
| EV to Sales | 62959.86 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 149.00M |
| EPS (TTM) | -1.50 |
| FCF per share (TTM) | -1.35 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 4.00K |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -11.46M |
| Net income (TTM) | -11.23M |
| EPS (TTM) | -1.50 |
| EPS (1y forward) | -0.23 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | -214748.36% |
| Profit margin (TTM) | -214748.36% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 5.23M |
| Net receivables | 18.00K |
| Total current assets | 6.83M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 6.97M |
| Accounts payable | 1.43M |
| Short/Current long term debt | 211.00K |
| Total current liabilities | 3.48M |
| Total liabilities | 3.76M |
| Shareholder's equity | 3.21M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -10.08M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -10.08M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -349.50% |
| Return on Assets | -160.99% |
| Return on Invested Capital | -327.96% |
| Cash Return on Invested Capital | -294.60% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.71 |
| Daily high | 1.76 |
| Daily low | 1.65 |
| Daily Volume | 2.44M |
| All-time high | 44820.00 |
| 1y analyst estimate | 13.40 |
| Beta | 1.61 |
| EPS (TTM) | -1.50 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| PALI | S&P500 | |
| Current price drop from All-time high | -100.00% | -1.82% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 10 Sep 2025 | 9 Mar 2009 |
| Avg drop from high | -98.89% | -10.84% |
| Avg time to new high | 604 days | 12 days |
| Max time to new high | 1208 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
253.31M
Marketcap category
Small-cap
Description
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.
Employees
8
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page